ArticleJournal of thrombosis and thrombolysis2014
Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory tests.
Article in Journal of thrombosis and thrombolysis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Rapid assessment of direct oral anticoagulants in acute stroke-An educational systematic review.European stroke journal · 2025Pooled it
- "In Less than No Time": Feasibility of Rotational Thromboelastometry to Detect Anticoagulant Drugs Activity and to Guide Reversal Therapy.Journal of clinical medicine · 2022Review
- Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study.Journal of thrombosis and thrombolysis · 2020Article
- Exploring the effect of factor Xa inhibitors on rotational thromboelastometry: a case series of bleeding patients.Journal of thrombosis and thrombolysis · 2019Article
- Are techniques for general anesthesia less invasive than procedures for cataract surgery?Eye (London, England) · 2017Article
- The influence of residual apixaban on bleeding complications during and after catheter ablation of atrial fibrillation.Journal of arrhythmia · 2017Article
- Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants.Vascular health and risk management · 2017Review
- Laboratory monitoring of direct oral anticoagulants (DOACs)-The perfect storm?Annals of translational medicine · 2017Article
- Real-world monitoring of direct oral anticoagulants in clinic and hospitalization settings.SAGE open medicine · 2017Article
- Dabigatran approaching the realm of heparin-induced thrombocytopenia.Blood research · 2016Review
- Tooth extraction in patients taking nonvitamin K antagonist oral anticoagulants.Journal of dental sciences · 2016Article
- The evolution of anticoagulant therapy.Blood transfusion = Trasfusione del sangue · 2016Review
- A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample.Journal of thrombosis and thrombolysis · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of patients diagnosed with atrial fibrillation who will be candidates for antithrombotic therapy with direct oral anticoagulants (i.e., dabigatran, rivaroxaban, apixaban and edoxaban) is exponentially arising worldwide, thus posing substantial economic and organizational challenges for their urgent monitoring. Due to long turnaround time and inherent technical complexity, liquid chromatography techniques are unsuitable for rapid assessment of their concentration. Even the use of surrogate tests such as thrombin clotting time or anti-factor Xa activity carries some economic and technical drawbacks. Based on literature data, we have hence developed an algorithm based on first-line tests for urgent screening of the anticoagulant effect of direct oral anticoagulants, which entails activated partial thromboplastin time (aPTT) for dabigatran and prothrombin time (PT) for rivaroxaban. Although these tests also display a concentration-dependent prolongation in patients taking apixaban and edoxaban, neither of them is sufficiently sensitive for providing accurate estimation of the pharmacodynamic effect, so that the measurement of anti-factor Xa activity remains the most suitable approach in patients taking these drugs. According to literature data, this strategy appears suitable to reliably define the thrombotic or bleeding risk in an urgent setting, contextually saving precious laboratory resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.